Mycophenolate mofetil and calcineurin-inhibitor reduction: Recent progress: Minireview

American Journal of Transplantation

Volumn 9, Issue 11, 2009, Pages 2447-2452

  Grinyó, Josep M ^a   Cruzado, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Calcineurin inhibitor agents; Mycophenolate mofetil

Indexed keywords

BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; CHRONIC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ACUTE DISEASE; CALCINEURIN; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 70350131319     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02812.x     Document Type: Short Survey

References (36)

1. Grinyó JM, Cruzado JM. Steroid or calcineurin inhibitor-sparing immunosuppressive protocols. Contrib Nephrol 2005 146 : 30 42.
2. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000 11 : 1910 1917.
3. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997 63 : 618.
4. Moore J, Middleton L, Cockwell P et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 2009 87 : 591 605.
5. Haller M, Oberbauer R. Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation. Transpl Int 2009 22 : 69 77.
6. Ekberg H. Calcineurin inhibitor sparing in renal transplantation. Transplantation 2008 86 : 761 767.
7. Zanker B, Schneeberger H, Rothenpieler U et al. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: First-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 1998 66 : 44 49.
8. Grinyó JM, Gil-Vernet S, Cruzado JM et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: Results after 5 years. Transpl Int 2003 16 : 820 827.
9. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001 71 : 1282 1287.
10. Ekberg H, Grinyó J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007 7 : 560 570.
11. Ekberg H, Tedesco-Silva H, Demirbas A et al. ELITE-SYMPHONY Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562 2575.
12. Grinyó JM, Ekberg H, Mamelok RD et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: The SYMPHONY pharmacokinetic substudy. Nephrol Dial Transplant 2009 24 : 2269 2276.
13. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007 7 : 2496 2503.
14. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the SYMPHONY study: Observational results 3 years after transplantation. Am J Transplant 2009. DOI : 10.1111/j.1600 - 6143.2009.02726.x
15. Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006 6 : 1991 1999.
16. Vincenti F, Larsen C, Durrbach A et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770 781.
17. Hueso M, Bover J, Serón D et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998 66 : 1727 1731.
18. Grinyó JM, Cruzado JM, Millán O et al. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 2004 78 : 1400 1403.
19. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001 59 : 1567 1573.
20. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004 4 : 655 662.
21. Dudley C, Pohanka E, Riad H et al. Mycophenolate Mofetil Creeping Creatinine Study Group. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005 79 : 466 475.
22. Tannuri U, Gibelli NE, Maksoud-Filho JG et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: Experience of a single center. Pediatr Transplant 2007 11 : 82 86.
23. Orlando G, Baiocchi L, Cardillo A et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 2007 13 : 46 54.
24. Ko HH, Greanya E, Lee TK, Steinbrecher UP, Erb SR, Yoshida EM. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor- induced renal impairment. Ann Hepatol 2008 7 : 376 380.
25. Reich DJ, Clavien PA, Hodge EE, MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 2005 80 : 18 25.
26. Aleksic I, Baryalei M, Busch T et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000 69 : 1586 1590.
27. Groetzner J, Meiser B, Landwehr P et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004 77 : 568 574. (Pubitemid 38282814)
28. Smak Gregoor PJ, van Gelder T, van Besouw NM, Van Der Mast BJ, IJzermans JN, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000 70 : 143 148.
29. Smak Gregoor PJ, de Sévaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002 13 : 1365 1373.
30. Abramowicz D, Manas D, Lao M et al. Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 2002 74 : 1725 1734.
31. Abramowicz D, Del Carmen Rial M, Vitko S et al. Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005 16 : 2234 2240.
32. Schnuelle P, Van Der Heide JH, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002 13 : 536 543.
33. Hazzan M, Labalette M, Copin MC et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol 2005 16 : 2509 2516.
34. Hazzan M, Buob D, Labalette M et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006 82 : 657 662.
35. Pascual J, Bloom D, Torrealba J et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008 8 : 1529 1536.
36. Bestard O, Nickel P, Cruzado JM et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008 19 : 1419 1429.